个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Recovery-model: A model for CAR T-cell-related thrombocytopenia in relapsed/refractory multiple myeloma

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Li Zhe[1] * ; Que Yimei[1] * ; Wang Di[1,3] * ; Lu Jie[2] ; Li Chunhui[1] ; Xu Menglei[1] ; Wang Zhiqiong[1,3] ; Yu Qiuxia[1] ; Long Xiaolu[1] ; An Ning[1] ; Xiao Yi[1,3] ; Li Chunrui[1,3,*1] ;
单位： [1]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China [2]Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China [3]Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei 430030, China
出处：
DOI： 10.1016/j.thromres.2023.05.016
ISSN：

关键词： Cytokine release syndrome Relapsed/refractory multiple myeloma Chimeric antigen receptor T cell therapy Platelet

摘要：
Patients with multiple myeloma (MM) treated with anti-B cell maturation antigen (BCMA) and chimeric antigen receptor (CAR) T-cell therapy tend to show delayed platelet recovery.This single-center retrospective observational study included a cohort of patients with MM treated with anti-BCMA CAR-T cells in ChiCTR-OPC-16009113, ChiCTR1800018137, and ChiCTR1900021153.Fifty-eight patients with MM treated with anti-BCMA CAR-T cells were included. Delayed platelet recovery (platelet count not recovering to 50 × 109/L within 28 days) was observed in 36 % of patients. Regression analysis identified several factors that influenced platelet recovery, and accordingly, a Recovery-Model was developed. A high Recovery-Model score indicates a greater risk of delayed platelet recovery after CAR-T cell infusion and reflects the risk of hematologic toxicity. The model's predictive biomarkers included baseline platelet count, baseline hemoglobin level, logarithm of baseline Ferritin level, and cytokine release syndrome grade. Finally, survival analysis showed a significant relationship between overall survival, delayed platelet recovery (p = 0.0457), and a high Recovery-Model score (p = 0.0011).Inflammation-related factors and bone marrow reserves are associated with delayed platelet recovery. Therefore, we developed a model to predict the risk of delayed platelet recovery and hematological toxicity in relapsed/refractory patients with MM after anti-BCMA CAR-T cell treatment.Copyright © 2023 Elsevier Ltd. All rights reserved.

基金：
This work was supported by funding from the National Natural Science Foundation of China (81873452 and 82170223, to Dr. Chunrui Li), the Clinical Research Program of Huazhong University of Science and Technology affiliated Tongji Hospital (2020003 to Dr. Chunrui Li).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 3 区 医学
小类 | 3 区 外周血管病 3 区 血液学
最新[2025]版：
大类 | 3 区 医学
小类 | 2 区 血液学 3 区 外周血管病
JCR分区：
出版当年[2021]版：
Q1 HEMATOLOGY Q1 PERIPHERAL VASCULAR DISEASE
最新[2023]版：
Q1 HEMATOLOGY Q1 PERIPHERAL VASCULAR DISEASE

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者单位： [1]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China [3]Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei 430030, China [*1]Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, Hubei 430030, China.
推荐引用方式(GB/T 7714)：
Li Zhe,Que Yimei,Wang Di,et al.Recovery-model: A model for CAR T-cell-related thrombocytopenia in relapsed/refractory multiple myeloma[J].THROMBOSIS RESEARCH.2023,227:62-70.doi:10.1016/j.thromres.2023.05.016.
APA：
Li Zhe,Que Yimei,Wang Di,Lu Jie,Li Chunhui...&Li Chunrui.(2023).Recovery-model: A model for CAR T-cell-related thrombocytopenia in relapsed/refractory multiple myeloma.THROMBOSIS RESEARCH,227,
MLA：
Li Zhe,et al."Recovery-model: A model for CAR T-cell-related thrombocytopenia in relapsed/refractory multiple myeloma".THROMBOSIS RESEARCH 227.(2023):62-70

相关文献

[1]Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function [2]The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies [3]Macrophage, the potential key mediator in CAR-T related CRS [4]Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas [5]Patients' experience with chimeric antigen receptor T-cell therapy for DLBCL in China: a qualitative study [6]Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy [7]Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients [8]The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook [9]Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future [10]Anti-CD30 Chimeric Antigen Receptor T Cell Therapy for CD30+ Relapsed/Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients

资源点击量：428 今日访问量：0 总访问量：412 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）